SOURCE: Cardima, Inc.

June 16, 2008 08:45 ET

Cardima at Cardiostim June 18-21, 2008: Dr. Sanjeev Saksena Will Speak on Linear Ablation at Cardiostim Highlighting Cardima's EP and Surgical Programs

FREMONT, CA--(Marketwire - June 16, 2008) - Cardima, Inc. (OTCBB: CADM) Cardima will be represented at Cardiostim 2008: The 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques by Dr. Sanjeev Saksena. Cardiostim 2008 will take place on June 18-21 in Nice, France. Dr. Saksena is a trained Cardiologist and Cardiac Electrophysiologist with an international reputation. He will give an important presentation on developments in linear ablation, and Cardima's work in both Electrophysiology and Surgical programs will be highlighted.

Cardiostim is a significant meeting attended by leading physicians, faculty and industry figures worldwide. Cardima's CEO, Robert Cheney, will also attend to assist Dr. Saksena in presenting Cardima's important clinical work to industry representatives and physicians. In commenting on Cardima's involvement at Cardiostim, Mr. Cheney stated: "Cardima is indeed fortunate to have a physician of Dr. Saksena's reputation highlighting our important clinical developments and bringing attention to our work in developing a safe, fast and effective clinical treatment for atrial fibrillation."

Dr. Saksena commented on the upcoming Cardiostim presentation: "Cardima is a unique company since it has successful clinical programs for linear ablation in both Electrophysiology as well as in Surgery. In this sense, Cardima has really positioned itself as a leader in the linear ablation field. Linear ablation is becoming more and more important for the clinical treatment of AF and other rhythm problems that require the creation of linear lesions. Cardima's technology is very adaptable and can be fashioned to create the long, transmural linear lesions necessary for effective treatment."

Dr. Saksena is Clinical Professor of Medicine at UMDNJ-Robert Wood Johnson School of Medicine, and Medical Director of the Electrophysiology Research Foundation. He has been the Director of the Cardiovascular Institute comprised of the Divisions of Cardiology and Cardiac Surgery at PBI Regional Medical Center from 1999-2004 and Director of the Arrhythmia & Pacemaker Service from 1989. He has been President of the North American Society of Pacing and Electrophysiology (NASPE/HRS) and Chair of its Government Relations Committee. He is currently a member of the governmental affairs committees for the Heart Rhythm Society and the American College of Cardiology.

Dr. Saksena played a key role in the growth of the cardiology and cardiac surgery departments in his institutions as well as the restructuring of national organizations such as NASPE to the Heart Rhythm Society. Dr. Saksena has participated in many clinical trials and has contributed extensively to leading edge academic research in the field of cardiology.

As one of the world's leading experts in the field of Cardiology and Electrophysiology, Dr. Saksena is the Founding editor and current Editor-in-Chief of the Journal of Interventional Cardiac Electrophysiology, has been the Editor of the Government Relations column for PACE, and remains an active consultant to governmental and private health care organizations. He has been an active clinical and applied basic science investigator since 1980, has held grants from NHLBI, industry, and the American Heart Association. In this period, he has authored/co-authored over 350 abstracts, 250 articles, and 60 book chapters. He is editor/co-editor of 4 journal supplements and co-editor of 5 books and has most recently co-edited a new textbook titled "Electrophysiological Disorders of the Heart." He is currently working on a new text on "Interventional Cardiac Electrophysiology."

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT® Series of diagnostic catheters, the NAVIPORT® Series of guiding catheters, the REVELATION® Series of ablation catheters, the Surgical Ablation System with its series of ablation probes, and the INTELLITEMP® Energy Management Device Series for RF (radiofrequency) energy management. These devices are CE marked and/or received U.S. FDA 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) with CE mark approval in Europe; it is not yet commercially available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements, including but not limited to Cardima's development of a safe, fast and effective clinical treatment for AF, and the adaptability of its technology to create a long, transmural linear lesions necessary for the effective treatment for AF. Potential risks and uncertainties include, but are not limited to: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure FDA approval for the EP ablation applications in the USA and CE mark for the Surgical Ablation probe series with Sheath. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, the Company's Quarterly Report on Form 10-QSB and in the Company's other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information